JP2002030084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002030084A5 JP2002030084A5 JP2000217709A JP2000217709A JP2002030084A5 JP 2002030084 A5 JP2002030084 A5 JP 2002030084A5 JP 2000217709 A JP2000217709 A JP 2000217709A JP 2000217709 A JP2000217709 A JP 2000217709A JP 2002030084 A5 JP2002030084 A5 JP 2002030084A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- azabicyclo
- thiophen
- octane
- azabicycloalkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- RHJDMHSBBRFVQT-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzothiophen-2-yl)ethanone Chemical compound C1=CC=C2SC(C(CC3C4CCN(CC4)C3)=O)=CC2=C1 RHJDMHSBBRFVQT-UHFFFAOYSA-N 0.000 description 6
- MBQTZDNDJHEQDS-UHFFFAOYSA-N 3-[2-(1-benzothiophen-2-yl)ethyl]-1-azabicyclo[2.2.2]octane Chemical compound C1N(CC2)CCC2C1CCC1=CC2=CC=CC=C2S1 MBQTZDNDJHEQDS-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- -1 Benzo [b] thiophen-2-yl Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GFYPTKLMKVKMDV-HNNXBMFYSA-N (3r)-3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CO[C@@H]3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-HNNXBMFYSA-N 0.000 description 2
- GFYPTKLMKVKMDV-OAHLLOKOSA-N (3s)-3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CO[C@H]3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-OAHLLOKOSA-N 0.000 description 2
- SHRLWGYNTYFYTI-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl(1-benzothiophen-2-yl)methanone Chemical compound C1=CC=C2SC(C(C3C4CCN(CC4)C3)=O)=CC2=C1 SHRLWGYNTYFYTI-UHFFFAOYSA-N 0.000 description 2
- ZJJRKBHGYKDFOG-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1,3-benzothiazol-2-yl)ethanone Chemical compound C1=CC=C2SC(C(CC3C4CCN(CC4)C3)=O)=NC2=C1 ZJJRKBHGYKDFOG-UHFFFAOYSA-N 0.000 description 2
- FMDNXPDPJHMQEM-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(CC3C4CCN(CC4)C3)=O)=CC2=C1 FMDNXPDPJHMQEM-UHFFFAOYSA-N 0.000 description 2
- GFYPTKLMKVKMDV-UHFFFAOYSA-N 3-(1-benzothiophen-2-ylmethoxy)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(COC3C4CCN(CC4)C3)=CC2=C1 GFYPTKLMKVKMDV-UHFFFAOYSA-N 0.000 description 2
- ZOGYPQAMAFELAL-UHFFFAOYSA-N 3-(1-benzothiophen-2-ylmethyl)-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CC3C4CCN(CC4)C3)=CC2=C1 ZOGYPQAMAFELAL-UHFFFAOYSA-N 0.000 description 2
- DLQOQDWFQJABBK-UHFFFAOYSA-N 3-[3-(1-benzothiophen-2-yl)propyl]-1-azabicyclo[2.2.2]octane Chemical compound C1=CC=C2SC(CCCC3C4CCN(CC4)C3)=CC2=C1 DLQOQDWFQJABBK-UHFFFAOYSA-N 0.000 description 2
- LRTRRSAXRXNUKV-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1C(=O)CC3CN4CCC3CC4 Chemical compound CN1C2=CC=CC=C2N=C1C(=O)CC3CN4CCC3CC4 LRTRRSAXRXNUKV-UHFFFAOYSA-N 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- CDAVRNSZZUNKKJ-UHFFFAOYSA-N 3-(1-azabicyclo[2.2.2]octan-3-yl)-1-(1-benzothiophen-2-yl)propan-1-one Chemical compound C1=CC=C2SC(C(CCC3C4CCN(CC4)C3)=O)=CC2=C1 CDAVRNSZZUNKKJ-UHFFFAOYSA-N 0.000 description 1
- 229940122656 Alpha-7 nicotinic receptor agonist Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217709A JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217709A JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002030084A JP2002030084A (ja) | 2002-01-29 |
| JP2002030084A5 true JP2002030084A5 (enExample) | 2010-07-08 |
| JP4616971B2 JP4616971B2 (ja) | 2011-01-19 |
Family
ID=18712778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000217709A Expired - Fee Related JP4616971B2 (ja) | 2000-07-18 | 2000-07-18 | １−アザビシクロアルカン化合物およびその医薬用途 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4616971B2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| EP1432707B1 (en) | 2001-10-02 | 2012-03-28 | Pharmacia & Upjohn Company LLC | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) * | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CN1675204A (zh) * | 2002-06-10 | 2005-09-28 | 拜耳医药保健股份公司 | 2－杂芳基甲酰胺 |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| MXPA05001702A (es) * | 2002-08-14 | 2005-04-19 | Neurosearch As | Derivados de quinuclidina novedosos y su uso. |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| ES2462545T3 (es) | 2002-12-06 | 2014-05-23 | The Feinstein Institute For Medical Research | Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico |
| DE602004010299T2 (de) | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
| RU2417225C2 (ru) | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| JP2007534692A (ja) | 2004-04-22 | 2007-11-29 | メモリー・ファーマシューティカルズ・コーポレイション | インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用 |
| JP2007538011A (ja) | 2004-05-07 | 2007-12-27 | メモリー・ファーマシューティカルズ・コーポレイション | １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用 |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| BRPI0517494A (pt) | 2004-12-22 | 2008-10-14 | Memory Pharm Corp | composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi |
| FR2884822B1 (fr) * | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| WO2008118742A1 (en) * | 2007-03-23 | 2008-10-02 | Abbott Laboratories | Azaadamantane ester and carbamate derivatives and methods of use thereof |
| CA2894860C (en) | 2008-11-19 | 2018-11-06 | Gerhard Koenig | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| MX357676B (es) | 2010-05-17 | 2018-07-18 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. |
| EP3666272A1 (en) | 2012-05-08 | 2020-06-17 | Forum Pharmaceuticals Inc. | Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967284A (ja) * | 1982-07-13 | 1984-04-16 | サンド・アクチエンゲルシヤフト | インドリルカルボン酸ピペリジルエステル誘導体 |
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| JP4163263B2 (ja) * | 1995-04-06 | 2008-10-08 | 矢崎総業株式会社 | 防水コネクタ |
-
2000
- 2000-07-18 JP JP2000217709A patent/JP4616971B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006509749A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| WO2002057252A3 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| JP2005519908A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| JP2004535436A5 (enExample) | ||
| JP2006500394A5 (enExample) | ||
| WO2002016357A3 (en) | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) | |
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| RU2000128658A (ru) | Тиенилазолилалкоксиэтанамны, их производные и их применение в качестве лекарственных средств | |
| JP2002527414A5 (enExample) | ||
| WO2002016356A3 (en) | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) | |
| JP2002513793A5 (enExample) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2003503449A5 (enExample) | ||
| JP2003502367A5 (enExample) | ||
| DE50011034D1 (de) | N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| JP2005538111A5 (enExample) | ||
| JP2005505583A5 (enExample) | ||
| JP2004315496A5 (enExample) | ||
| JP2007507474A5 (enExample) | ||
| JP2003513075A5 (enExample) |